openPR Logo
Press release

Non Small Cell Lung Cancer Therapeutics Market: Global Industry Analysis, Prevention, Management, Mechanisms and Symptoms Report 2015 - 2023

07-14-2016 12:29 PM CET | Health & Medicine

Press release from: Researchmoz Global Pvt. Ltd.

Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023 Size and Share Published in 2015-11-27 Available for US$ 5795 at Researchmoz.us

Description

Fuul Report@$# http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.

The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.

Based on drug class, the NSCLC therapeutics market has been segmented into six major categories: angiogenesis inhibitor, epidermal growth factor receptor blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/ PD-L1 inhibitor. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Download Sample of this Report at: http://www.researchmoz.us/enquiry.php?type=S&repid=497268

Geographically, the global NSCLC therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, China, and Rest of Asia Pacific), and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global NSCLC therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.

The global non-small cell lung cancer therapeutics market is segmented as follows:

Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)

Overview

Angiogenesis Inhibitor

Avastin (bevacizumab)

Cyramza (Ramucirumab)

Epidermal Growth Factor Receptor Blocker

Tarceva (erlotinib)

Gilotrif (afatinib)

Iressa (gefitinib)

Kinase Inhibitor

Xalkori (crizotinib)

Zykadia (ceritinib)

Microtubule Stabilizer

Abraxane (paclitaxel protein bound)

Docetaxel

Folate Antimetabolites

Alimta (pemetrexed)

PD-1/ PD-L1 Inhibitor

Opdivo (nivolumab)

Keytruda (pembrolizumab)

Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market

Overview

Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)

Avelumab - Pfizer, Inc.

MPDL3280A - Roche

MEDI4736 - AstraZeneca

Abemaciclib - Eli Lilly and Company

Others

Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)

Overview

North America

U.S.

Canada

Europe

U.K.

Germany

Rest of Europe

Asia Pacific

Japan

China

Rest of Asia Pacific

Rest of the World

Make an Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=497268

Table of Content

1. Preface

1.1. Report Description

1.2. Research Methodology

1.3. Market Segmentation

2. Executive Summary

2.1. Market Snapshot

2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.

Contact Us:

ResearchMoz
Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
sales@researchmoz.us
http://www.researchmoz.us/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non Small Cell Lung Cancer Therapeutics Market: Global Industry Analysis, Prevention, Management, Mechanisms and Symptoms Report 2015 - 2023 here

News-ID: 348909 • Views:

More Releases from Researchmoz Global Pvt. Ltd.

Online Fitness Services Market Size, Share, Growth, Trend, Drivers and Restraint 2021-2027
Online Fitness Services Market Size, Share, Growth, Trend, Drivers and Restraint …
Online Fitness Services Market is predicted to grow at substantial compounded annual rate of growth (CAGR) during the forecast period 2020-2027. The markets growth is analysed by studying multiple determinants like Market Drivers, Trends, Challenges, Opportunities, Restraints, and Competition. It includes detailed analysis of the market on the basis of competitive profiles of key players, market segmentations, geographical analysis and economic models. The influence of Covid-19 on the market is discussed
Senior Living Market Current Status and Challenges with Future Opportunities to 2027
Senior Living Market Current Status and Challenges with Future Opportunities to …
The Senior Living Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Senior Living industry and data for creating strategies to increase market growth and success. The report estimates market size, price, revenue, gross margin
Testing and Inspection Services Market 2020 Analysis includes Growth, Challenges and development Strategies forecast to 2027
Testing and Inspection Services Market 2020 Analysis includes Growth, Challenges …
The Testing and Inspection Services Market Report provides a detailed assessment of the market by highlighting information on various aspects including the global market, including drivers, restraints, opportunities, threats and development trends, competitive landscape analysis, and Growth status of key regions. The report provides comprehensive numerical analysis of the Testing and Inspection Services industry and data for creating strategies to increase market growth and success. The report estimates market size,
Proctoring Solution for Online Exams Market 2021 Leading Players, Industry Updates, Comprehensive Analysis and Forecast 2027
Proctoring Solution for Online Exams Market 2021 Leading Players, Industry Updat …
The study provides an in-depth study of the Proctoring Solution for Online Exams Market's trends and opportunities. On the basis of recent events and historical data, it makes figurative estimates and forecasts the future for the coming years. Moreover, the market document holds a substantial importance when it is about explaining market definition, classifications, applications and engagements. With the study of competitor analysis conducted in this Proctoring Solution for Online

All 5 Releases


More Releases for NSCLC

Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants. Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904 Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Global Non-Small Cell Lung Cancer (NSCLC) Market- Current and Future Players
"The Report Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" GlobalData has released its pharma report, Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer. Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how